Replies to post #19114 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT 2Q19 sales by business segment:

 
 Medical devices* 39% (+11% YoY in const currency)    
 Diagnostics      24% ( +6% YoY in const currency)    
 Nutrition        24% ( +5% YoY in const currency)   
 Drugs†           14% ( +6% YoY in const currency)

64% of overall sales were ex-US.

*Including diabetes care.
†Branded generics in emerging markets.

[DewDiligence]

ABT authorizes new $3B buyback—in addition to ~$800M remaining on 2014 authorization:

https://www.sec.gov/ix?doc=/Archives/edgar/data/1800/000141057819001645/tv530928_8k.htm

It makes sense… the stock is cheap!

ABT reports 3Q19 results tomorrow.

[DewDiligence]

ABT 3Q19 items…

PR:
https://www.abbottinvestor.com/static-files/b72fda5c-6539-4fe2-8bfb-d1c37f1b3a10

Mini slide set:
https://www.abbottinvestor.com/static-files/29bcecc3-6aa6-453d-b472-57db91204523

Non-GAAP 2019 EPS guidance was narrowed to $3.23-$3.25 (from the prior range of $3.21-3.27). GAAP 2019 EPS guidance was lowered slightly at the top end to $2.06-2.08 (from the prior range of $2.06-2.12).